BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 05-08-2025: Outcome of Board Meeting

Balaxi Pharmaceuticals' board approved the consolidated financial results for the quarter ended June 30, 2025, reporting revenue of ₹70.74 Cr and a net profit of ₹0.29 Cr. The company also shared positive updates on its Jadcherla plant: all machine qualifications (IQ, OQ, PQ) are complete. Water validation and vendor qualification are progressing, expected to finish by August end. With a manufacturing test license secured, stability batch production is anticipated to begin early September. Furthermore, its wholly-owned subsidiary, Balaxi Global DMCC, acquired 100% stake in Balaxi Healthcare Nicaragua.